Ipsens’ partner, Exelixis, announced phase 1 trial results for cabozantinib in combination with nivolumab in advanced genitourinary tumors

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria